Table 2

Treatment-emergent adverse events at incidence ≥5% in the LY2140023 group, or significantly different between groups
Event, n (%) LY2140023 SOC P value
(N = 130) (N = 131)
Patients with ≥ TEAE 100 (76.9) 94 (71.8) .396
Insomnia 20 (15.4) 10 (7.6) .054
Anxiety 19 (14.6) 10 (7.6) .079
Headache 16 (12.3) 10 (7.6) .222
Vomiting 15 (11.5) 3 (2.3) .003*
Schizophrenia 12 (9.2) 11 (8.4) .831
Agitation 11 (8.5) 2 (1.5) .011*
Blood CPK increases 10 (7.7) 14 (10.7) .521
Nausea 10 (7.7) 4 (3.1) .108
Dyspepsia 8 (6.2) 1 (0.8) .019*
Nasopharyngitis 7 (5.4) 3 (2.3) .217
Akathisia 1 (0.8) 9 (6.9) .019*
Weight increased 0 (0.0) 8 (6.1) .007*

Abbreviations: CPK Creatinine phosphokinase, n/N Number of patients, SOC Standard of care, TEAE Treatment-emergent adverse events.

Groups: LY2140023, LY2140023 monohydrate, SOC, Standard-of-care.

*P < .05, LY2140023 versus SOC. Events significantly different between treatment groups are highlighted in bold text.

Adams et al.

Adams et al. BMC Psychiatry 2013 13:143   doi:10.1186/1471-244X-13-143

Open Data